Aligos Therapeutics, Inc. (ALGS) — 8-K Filings

8-K Filings (20)

• 8-K Filing — Nov 6, 2025
• Aligos Therapeutics Files 8-K on Financials — Aug 6, 2025 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and ex
• Aligos Therapeutics Files 8-K with Corporate Governance Updates — Jun 26, 2025 Risk: medium
  On June 25, 2025, Aligos Therapeutics, Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure of directo
• Aligos Therapeutics Files 8-K on Financials — May 6, 2025 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as providing financial statements
• Aligos Therapeutics Files 8-K on Financials — Mar 10, 2025 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on March 10, 2025, to report on its results of operations and financial condition. The filing does not contain specific f
• Aligos Therapeutics Files 8-K with Key Agreements and Disclosures — Feb 12, 2025 Risk: medium
  On February 11, 2025, Aligos Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, enga
• Aligos Therapeutics Announces Executive and Director Changes — Feb 3, 2025 Risk: medium
  Aligos Therapeutics, Inc. announced on January 30, 2025, changes in its board and executive compensation. Specifically, the company reported the departure of ce
• Aligos Therapeutics Files 8-K on Operations — Nov 6, 2024 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition. The filing does not contain specific
• Aligos Therapeutics Files 8-K Report — Sep 5, 2024 Risk: low
  On September 3, 2024, Aligos Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No spe
• Aligos Therapeutics Files 8-K on Security Holder Rights — Aug 19, 2024 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on August 19, 2024, reporting material modifications to security holder rights and amendments to its articles of incorpor
• Aligos Therapeutics Announces Board and Executive Changes — Aug 8, 2024 Risk: medium
  Aligos Therapeutics, Inc. announced on August 7, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departu
• Aligos Therapeutics Files 8-K on Financials — Aug 6, 2024 Risk: low
  On August 6, 2024, Aligos Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• Aligos Therapeutics Elects New Directors, Amends Bylaws — Jun 28, 2024 Risk: medium
  Aligos Therapeutics, Inc. announced on June 27, 2024, a series of significant corporate actions. These include the election of two new directors, Dr. David P. G
• Aligos Therapeutics Faces Nasdaq Delisting Notice — May 31, 2024 Risk: high
  Aligos Therapeutics, Inc. filed an 8-K on May 29, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is facing po
• Aligos Therapeutics Faces Nasdaq Delisting Warning — May 22, 2024 Risk: high
  Aligos Therapeutics, Inc. announced on May 21, 2024, that it received a notice from The Nasdaq Stock Market indicating non-compliance with listing rules. The co
• Aligos Therapeutics Announces Executive and Board Changes — May 15, 2024 Risk: medium
  On May 9, 2024, Aligos Therapeutics, Inc. announced changes in its board of directors and executive compensation. Dr. Michael Y. Lin resigned as Chief Medical O
• Aligos Therapeutics Files 8-K on Financials — May 7, 2024 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhib
• Aligos Therapeutics Files 8-K for Operations and Financials — Mar 12, 2024 Risk: low
  Aligos Therapeutics, Inc. filed an 8-K on March 12, 2024, to report on its results of operations and financial condition, as well as to file financial statement
• Aligos Therapeutics Reports Executive Changes and Compensation Updates — Feb 28, 2024 Risk: medium
  Aligos Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting an event on February 27, 2024. The filing pertains to the departure of directors or certa
• Aligos Therapeutics Signals Potential Tender Offer Activity — Jan 25, 2024
  Aligos Therapeutics, Inc. filed an 8-K on January 25, 2024, indicating it is engaging in "Pre-commencement communications pursuant to Rule 13e-4(c) under the Ex

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX